Overview

A Study of Erythromycin and Rivaroxaban in Study Participants With Normal and Reduced Kidney Function

Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban when administered with erythromycin to study participants with mild or moderate renal impairment compared to the pharmacokinetics and pharmacodynamics of rivaroxaban administered to study participants with normal renal function.
Phase:
Phase 1
Details
Lead Sponsor:
Janssen Research & Development, LLC
Collaborator:
Bayer
Treatments:
Erythromycin
Erythromycin Estolate
Erythromycin Ethylsuccinate
Erythromycin stearate
Rivaroxaban